RemeGen Co., Ltd.
Status: Publicly traded
Direct answer
RemeGen Co., Ltd. is publicly traded on HKSE under the ticker 9995.HK.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an...
Can you invest in RemeGen Co., Ltd.?
Yes. RemeGen Co., Ltd. trades publicly on HKSE as 9995.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for RemeGen Co., Ltd.
Detailed equity research is provided by MarketSnap.